362 completed. 362 Phase 2, 49 Phase 1, 41 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 362 | Completed 362 |
| Phase 1 | 49 | Completed 49 |
| Phase 3 | 41 | Completed 41 |
Follow Neurodevelopmental Disorders: new trials by email Literature Review of Neurodevelopmental Disorders trials Research Report on Neurodevelopmental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models Bumetanide, Treatment as usual (TAU) - Autism Spectrum Disorder | Phase 2 | Completed | Fei Li | 66 | 2025-06-04 | 2026-04-29 |
| Efficacy of Nutritional Supplements on Children With Autism Spectrum Disorder Nutritional supplements, Treatment as usual (TAU) - Autism Spectrum Disorder | Phase 2 | Completed | Fei Li | 88 | 2025-04-01 | 2026-04-23 |
| The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder Cannabigerol, Placebo - Attention-Deficit/Hyperactivity Disorder | Phase 2 | Completed | University of Arkansas, Fayetteville | 67 | 2024-12-14 | 2026-11-09 |
| Prospective Pilot Trial to Address Feasibility and Safety of Oral Zinc in GNAO1 Associated Disorders Zinc Acetate Dihydrate - GNAO1, Dystonia | Phase 2 | Completed | Children's University Hospital Cologne, Germany | 13 | 2024-08-02 | 2026-02-03 |
| A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder Low Dose ARD-501, High Dose ARD-501, Placebo - Autism Spectrum Disorder | Phase 2 | Completed | Aardvark Therapeutics, Inc. | 5 | 2024-08-01 | 2025-05-09 |
| Safety and Efficacy of tPBM for Epileptiform Activity in Autism noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - Autism Spectrum Disorder, EEG With Periodic Abnormalities | Phase 2 | Completed | Richard Frye | 6 | 2024-07-01 | 2026-09-22 |
| Effect of Omega-3 Fatty Acid on Neurobehavioral Status of Children With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo Controlled Trial Omega 3 fatty acid, Placebo of Omega-3 fatty acid softgel capsule - Autism Spectrum Disorder | Phase 2 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 64 | 2023-09-19 | 2025-07-09 |
| Efficacy and Mechanism of Repetitive Transcranial Magnetic Stimulation in Children With Autism Spectrum Disorders repeated transcranial magnetic stimulation (continuous theta-burst stimulation), sham repeated transcranial magnetic stimulation - Autism Spectrum Disorder | Phase 2 / Phase 3 | Completed | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 200 | 2023-07-04 | 2026-05-19 |
| Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD) NRCT-101-SR, Placebo - ADHD | Phase 2 / Phase 3 | Completed | Neurocentria, Inc. | 223 | 2023-02-25 | 2025-06-03 |
| Virtual Reality Intervention for Skill Acquisition Support in Autism Spectrum Disorder (ASD) Floreo VR Building Social Connections, Sham - Autism Spectrum Disorder | Phase 2 | Completed | Floreo, Inc. | 30 | 2023-02-15 | 2025-02-26 |
| ADX-629 Therapy for Sjogren-Larsson Syndrome ADX-629 - Sjogren-Larsson Syndrome | Phase 1 / Phase 2 | Completed | University of Nebraska | 8 | 2023-01-02 | 2026-05-05 |
| Esketamine Combined With Dexmedetomidine Sedation in Head MRI Examination of Children With Autism Spectrum Disorder low dos dexmedetomidine, high dos dexmedetomidine, dexmedetomidine and esketamine - Autism Spectrum Disorder, Dexmedetomidine | Phase 2 | Completed | Maternal and Child Health Hospital of Hubei Province | 300 | 2022-12-01 | 2024-10-09 |
| Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder NTI164 - Autism Spectrum Disorder | Phase 2 / Phase 3 | Completed | Fenix Innovation Group | 54 | 2022-11-30 | 2026-09-10 |
| Micronutrient Supplementation in Children With ASD Micronutrient - Autism Spectrum Disorder | Phase 2 | Completed | University of California, San Francisco | 16 | 2022-11-14 | 2024-02-29 |
| ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) ML-004 (IR)/(ER) tablet, ML-004 Placebo - Autism Spectrum Disorder | Phase 2 | Completed | MapLight Therapeutics | 168 | 2022-09-13 | 2026-05-19 |
| A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus) NOE-105, Placebo - Childhood-Onset Fluency Disorder | Phase 2 | Completed | Noema Pharma AG | 75 | 2022-07-25 | 2026-02-20 |
| Epidiolex in Obsessive Compulsive Disorder and Related Disorders Cannabidiol - Obsessive-Compulsive Disorder, Trichotillomania (Hair-Pulling Disorder) | Phase 2 | Completed | University of Chicago | 4 | 2022-04-14 | 2026-07-29 |
| PDC-1421 Treatment in Adult Patients With ADHD PDC-1421 Capsule, Placebo - Attention-Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Completed | BioLite, Inc. | 99 | 2022-04-07 | 2026-05-06 |
| Methylphenidate in Childhood Apraxia of Speech Methylphenidate Hydrochloride, Placebo - Childhood Apraxia of Speech | Phase 2 | Completed | Murdoch Childrens Research Institute | 18 | 2022-03-14 | 2026-10-13 |
| A Study to Explore the Effect of Sepranolone in Tourette Syndrome Sepranolone - Tourette Syndrome, Tourette Syndrome in Adolescence | Phase 2 | Completed | Asarina Pharma | 26 | 2022-02-16 | 2023-06-09 |
Showing 20 of 362. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (129) · Autistic Disorder (105) · Autism Spectrum Disorder (94) · Tourette Syndrome (29) · Asperger Syndrome (16) · Anxiety Disorders (13) · Child Development Disorders, Pervasive (11) · Fragile X Syndrome (10) · Intellectual Disability (9) · Anxiety, Separation (8) · Generalized Anxiety Disorder (8) · Mental Disorders (8) · Phobia, Social (8) · Tic Disorders (8) · Conduct Disorder (7)
Mental Disorders (354) · Child Development Disorders, Pervasive (155) · Attention Deficit and Disruptive Behavior Disorders (132) · Nervous System Diseases (82) · Autism Spectrum Disorder (72) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (55) · Genetic Diseases, Inborn (53) · Pathological Conditions, Signs and Symptoms (52) · Signs and Symptoms (51) · Neurologic Manifestations (50) · Heredodegenerative Disorders, Nervous System (47) · Central Nervous System Diseases (41) · Brain Diseases (39) · Neurobehavioral Manifestations (34)
Methylphenidate (20) · Atomoxetine Hydrochloride (16) · Oxytocin (11) · Cognitive Behavioral Therapy (7) · Therapeutics (7) · Acetylcysteine (6) · Lisdexamfetamine Dimesylate (6) · pozanicline (6) · Aripiprazole (5) · Fatty Acids, Omega-3 (5) · Memantine (5) · Risperidone (5) · Sodium Chloride (5) · Sugars (5) · Tablets (5)
Stanford University (8) · University of California, Los Angeles (7) · University of California, San Francisco (7) · Holland Bloorview Kids Rehabilitation Hospital (6) · Massachusetts General Hospital (6) · New York State Psychiatric Institute (6) · Shire (6) · AbbVie (prior sponsor, Abbott) (5) · Eli Lilly and Company (5) · Neurocrine Biosciences (5) · Otsuka Pharmaceutical Development & Commercialization, Inc. (5) · University of North Carolina, Chapel Hill (5) · Alcobra Ltd. (4) · Arizona State University (4) · Children's Hospital Medical Center, Cincinnati (4)
United States (257) · Canada (29) · Germany (10) · Australia (9) · Israel (9) · Spain (9) · France (8) · China (7) · Italy (6) · Norway (6) · Poland (6) · United Kingdom (6) · Japan (5) · Taiwan (4) · Brazil (3)
Evdokia Anagnostou, M.D. (8) · Linmarie Sikich, MD (5) · Alexander Kolevzon, MD (4) · Craig Surman, MD (4) · James McCracken, MD (4) · Antonio Hardan, MD (3) · Frances R Levin, M.D. (3) · James B. Adams, PhD (3) · Mustafa Sahin, MD, PhD (3) · Richard P Malone, MD (3) · Robert L Hendren, DO (3) · Alan Percy, MD (2) · Ann Childress, M.D. (2) · Antonio Y Hardan, MD (2)
PMID 37811711, PMID 36006807, PMID 20732631, PMID 21156272, PMID 24001701, PMID 24144615, PMID 25988365, PMID 26763495, PMID 28202705, PMID 29029679, PMID 37460385, PMID 38114596, PMID 38363467, PMID 10341379, PMID 10385840, PMID 11514638, PMID 11918106, PMID 14605787, PMID 14662594, PMID 14733976, PMID 16041867, PMID 16102908, PMID 16481664, PMID 16540816, PMID 16890481, PMID 17109795, PMID 17284136, PMID 17352947, PMID 17520797, PMID 17631866, PMID 17671050, PMID 18315448, PMID 18469236, PMID 18544723, PMID 18555170, PMID 18632997, PMID 19186083, PMID 19309326, PMID 19398354, PMID 19487623, PMID 19491110, PMID 19849639, PMID 19877974, PMID 20048226, PMID 20145986, PMID 20215923, PMID 20406576, PMID 20445835, PMID 20445836, PMID 20445837
2018 (2), 2009 (1), 2014 (1), 2016 (1), 2017 (1), 2019 (1), 5KL2TR001109-05 (1), F31MH096375 (1), K23NS055733 (1), K24AA000301 (1), P50DA009236 (1), P50HD055784 (1), P50MH100023 (1), R01AA026859 (1), R01DA011444 (1)